Kalnik Matthew W. 4
4 · NABI BIOPHARMACEUTICALS · Filed Jul 21, 2010
Insider Transaction Report
Form 4
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
- Sale
Common Stock
2010-07-19$5.48/sh−1,625$8,905→ 45,725.104 total
Footnotes (1)
- [F1]The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.